Peptide News Digest

#Anticancer-Peptides

2 stories

Research · View digest

Discover Oncology 2026 Review: Antimicrobial Peptides as Anticancer Therapeutics — From Membrane Disruption to Vaccine Adjuvants

A 2026 Discover Oncology review (Springer Nature) consolidated the case for antimicrobial peptides (AMPs) as anticancer therapeutics across three mechanistic categories: direct cytotoxicity through cancer-cell-membrane disruption (the same cationic-amphipathic chemistry that makes AMPs antibacterial works on the negatively charged outer leaflet of cancer-cell membranes), intracellular targeting of mitochondria and DNA replication, and use as vaccine adjuvants that boost immune responses to neoantigens. The review joins the May 2026 International Journal of Peptide Research piece on peptide cancer vaccines, the Frontiers in Medicine April 2026 anticancer AMP review, and the Frontiers in Bioinformatics March 2026 computational AMP discovery review as part of the AMP-as-cancer-therapeutic literature wave. Clinical translation remains limited: AMP-based cancer drugs in development are mostly preclinical or Phase 1.

Research · View digest

Frontiers in Medicine 2026 Review: Antimicrobial Peptides Pull Double Duty as Anticancer Agents and Vaccine Adjuvants

A Frontiers in Medicine review published in 2026 consolidates the case for antimicrobial peptides (AMPs) as anticancer therapeutics and vaccine adjuvants. The cationic, amphipathic architecture that makes AMPs effective against bacterial membranes also enables selective electrostatic interactions with negatively charged malignant cell membranes — driving rapid membrane disruption and cell lysis. Beyond direct membrane effects, the review documents AMP-induced inhibition of DNA replication and protein synthesis, mitochondrial dysfunction, and tumor angiogenesis suppression. The piece also catalogs AMPs with adjuvant properties that boost vaccine immune responses against cancer and infectious disease. The work joins the Houston Methodist CAMPER MRSA paper, the Nature Communications few-shot Acinetobacter pipeline, and the Manchester penicillin-biosynthesis paper as part of the AMP wave through April–May 2026.